Phaseline

Companies › Beijing Continent Pharmaceutical

Beijing Continent Pharmaceutical: clinical trials, targets and expected readouts

4 active drug programs in 6 registered trials: 2 Phase 1, 2 Phase 3, 2 Phase 2; Gastroenterology, Cardiovascular, Genitourinary, Respiratory; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Hydronidone capsules
Pyridinone-based small molecule compound
–Phase 3Liver Fibrosis; Renal Insufficiency ChronicDec 2026
Pirfenidone Capsules–Phase 3Pneumoconiosis; Radiation-induced Lung InjuryDec 2026
F573 for injection–Phase 2Acute Liver Failure–
F230 tablets
Endothelin antagonist
–Phase 1Pulmonary Hypertension–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06899815F230 tabletsPhase 1Pulmonary HypertensionCardiovascularJul 2026
NCT05689645F573 for injectionPhase 2Acute Liver FailureGastroenterologySep 2026
NCT05288179Pirfenidone CapsulesPhase 3PneumoconiosisRespiratorySep 2026
NCT07262333Hydronidone capsulesPhase 1Renal Insufficiency ChronicGenitourinaryDec 2026
NCT07388680Pirfenidone CapsulesPhase 2Radiation-induced Lung InjuryRespiratoryDec 2026
NCT05905172Hydronidone capsulesPhase 3Liver FibrosisGastroenterologyJun 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Livzon Pharmaceutical Group Noorik Biopharmaceuticals Taisho Pharmaceutical Shin Poong Pharmaceutical Biocodex

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.